←Back to Expert Scholars
Translational Medicine / 转化医学BRCA-Associated Breast Cancer, PARP Inhibitors
Jennifer Keating Litton
MD
🏢MD Anderson Cancer Center🌐USA
Professor and Vice President, Clinical Research
70
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Jennifer Keating Litton led the EMBRACA trial of talazoparib in germline BRCA-mutated metastatic breast cancer that supported FDA approval. Her work advances PARP inhibitor use and germline-guided care. She directs clinical research strategy at MD Anderson.
Share:
🧪Research Fields 研究领域
metastatic breast cancer
BRCA
PARP inhibitors
talazoparib
germline genetics
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Jennifer Keating Litton 的研究动态
Follow Jennifer Keating Litton's research updates
留下邮箱，当我们发布与 Jennifer Keating Litton（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment